

Table 2. The levels of anti-elastin Ab in severity, asthma phenotypes and co-morbidities in patients with asthma

	Sputum	Serum
Severity of asthma		
Step 1	18.0 ± 4.18	76.7 ± 50.0
Step 2	10.2 ± 7.72	48.9 ± 16.5
Step 3	11.3 ± 8.17	67.3 ± 30.2
Step 4	8.93 ± 5.47	75.3 ± 26.3
Asthma phenotypes		
Allergic	9.40 ± 5.11	68.2 ± 29.8
Non-allergic	13.0 ± 8.55	57.5 ± 23.7
Adult-onset	11.4 ± 7.16	67.4 ± 29.7
Low %FEV <sub>1</sub>	10.4 ± 9.02	79.0 ± 30.0
Obesity	11.6 ± 8.08	72.3 ± 19.2
Co-morbidities (with / without)		
Allergic rhinitis	8.42 ± 6.29 / 13.2 ± 7.26	78.3 ± 33.2 / 60.4 ± 26.2
Hypertension	13.1 ± 9.37 / 10.9 ± 6.65	69.2 ± 21.9 / 66.8 ± 32.6
Diabetes	18.4 ± 6.22 / 9.37 ± 6.14 *	78.0 ± 17.9 / 64.5 ± 32.0
Dyslipidemia	18.9 ± 4.43 / 8.62 ± 5.86 **	60.1 ± 22.2 / 70.6 ± 32.6

Mean ±SD (µg/mL); \**P* < .05; \*\**P* < .01 between with and without co-morbidities.

No significant differences were observed between severities and between asthma phenotypes.